DTP's Rapid Expansion and the Safety Gap: EHR Integration is Key Challenge
DTP is Scaling Fast, the Safety Infrastructure is Not | PharmExec
Summary
Direct-to-Patient (DTP) models are rapidly expanding, driven by privacy concerns. However, these systems fail to feed prescription data into Electronic Health Records (EHRs), creating an 'EHR blind spot' that increases risks in medication management and drug interaction monitoring.
Details
The Direct-to-Patient (DTP) pharmaceutical distribution model is experiencing rapid market growth, fueled by patient demand for privacy. This trend is particularly visible in stigmatized areas like weight management or mental health. However, current first-generation platforms fail to transmit DTP prescriptions back to the patient's primary care physician or EHR. This creates a critical 'EHR blind spot,' which compromises medication reconciliation and adverse event management. While near-term fixes include downloadable summaries or one-click notifications for sharing data, long-term safety requires automatic integration into the EHR via FHIR APIs. The industry must build clinical safety infrastructure not due to regulatory mandate, but by pairing convenience with clinical accountability.
Original content copyright by respective publishers